Peking University Cancer Hospital & Institute: Carcinoma, Hepatocellular trials

The registry lists 11 Carcinoma, Hepatocellular studies with Peking University Cancer Hospital & Institute as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 8Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingNCT07882056Phase 2
• 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid TumorsNot yet recruitingNCT07639801Not applicable
• Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2
• Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCCRecruitingNCT05917431Phase 2
• The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular CarcinomaStatus unknownNCT05862181
• TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCCStatus unknownNCT04597970Phase 2
• The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04542837Phase 2
• Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04479527Phase 2
• The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular CarcinomaStatus unknownNCT03143140Not applicable
• Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After ResectionStatus unknownNCT02767375Phase 2/3
• A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma PatientsStatus unknownNCT02727309Phase 1/2